<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04381143</url>
  </required_header>
  <id_info>
    <org_study_id>GDPH-CH-2774</org_study_id>
    <nct_id>NCT04381143</nct_id>
  </id_info>
  <brief_title>ASPIrin in Reducing Events in Dialysis ( ASPIRED )</brief_title>
  <official_title>ASPIrin in Reducing Events in Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>George Clinical Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangdong Provincial People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      People with kidney failure requiring dialysis have a much higher risk of developing
      cardiovascular (CV) disease compared with the general population. A cardiac cause accounts
      for 58% of all deaths in patients with end stage kidney disease (ESKD). At the same time,
      this population has increased risks of clotting as well as bleeding episodes. While aspirin
      is known to reduce cardiovascular complications in the general population, evidence to
      support the use of aspirin in people with ESKD receiving dialysis therapy is currently
      lacking. The ASPIrin to Reduce Event in Dialysis (ASPIRED) trial will test whether aspirin
      use in dialysis patients safely improves outcomes compared with no aspirin use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ASPIRED is an investigator-initiated, multi-center, double-blind, parallel group,
      event-driven, pragmatic, registry-based randomized controlled trial that will define the
      value of low dose aspirin (100 mg daily) on cardiovascular events in people with ESKD
      receiving dialysis.

      The study will be conducted using the existing platform of the Chinese peritoneal dialysis
      (PD) and hemodialysis (HD) Dialysis Registry to screen, recruit and to collect study data as
      part of patient's routine clinical care during dialysis to improve efficiency and to minimize
      cost of a clinical trial.

      ASPIRED is an event driven trial with an anticipated duration of approximately 5 years.

      Randomization will be performed using a web-based system via a pass word protected encrypted
      website interface.

      The study procedure utilizes routine six-monthly clinic visits for study follow-up to
      increase efficiency and minimize the burden on participants.

      The analysis will be based on intention-to-treat principles. An independent Data Safety and
      Monitoring Board (DSMB) will established to monitor the study for safety and efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">April 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Pragmatic designs</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of major cardiovascular events (3-point MACE)</measure>
    <time_frame>From trial initiation to any event first occurrence, up to 4 years.</time_frame>
    <description>A composite of cardiovascular death, myocardial infarction, or ischemic stroke.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of the primary outcome plus all-cause death</measure>
    <time_frame>From trial initiation to any event first occurrence, up to 4 years.</time_frame>
    <description>A composite of cardiovascular death, myocardial infarction, ischemic stroke or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>From trial initiation to any event first occurrence, up to 4 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>From trial initiation to any event first occurrence, up to 4 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>From trial initiation to any event first occurrence, up to 4 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>From trial initiation to any event first occurrence, up to 4 years.</time_frame>
    <description>Death for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Coronary revascularization</measure>
    <time_frame>From trial initiation to any event occurrence, up to 4 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Fistula or graft thrombosis</measure>
    <time_frame>From trial initiation to any event occurrence, up to 4 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Haemorrhagic stroke</measure>
    <time_frame>From trial initiation to any event occurrence, up to 4 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Ischemic events</measure>
    <time_frame>From trial initiation to any event occurrence, up to 4 years.</time_frame>
    <description>Defined as a composite of myocardial infarction (MI), coronary death, ischemic stroke, or any revascularization procedure (i.e, exclusion of noncoronary cardiac deaths and strokes confirmed to be haemorrhagic).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Major bleeding</measure>
    <time_frame>From trial initiation to any event first occurrence, up to 4 years.</time_frame>
    <description>Major bleeding is defined based on modified International Society on Thrombosis and Haemostasis (ISTH) definition, including fatal bleeding, and/or symptomatic bleeding in a critical area or organ, such as intracranial, intra-spinal, intra-ocular, retro-peritoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, or bleeding into a surgical site requiring re-operation, and/or bleeding leading to hospitalization.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">9000</enrollment>
  <condition>CKD (Chronic Kidney Disease) Stage 5D</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin tablet 100mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet 1 pill daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 100 mg Oral Tablet</intervention_name>
    <description>Aspirin 100 mg tablets daily</description>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients who are entered into the Chinese PD and HD dialysis registry

          -  Expected requirement for ongoing maintenance dialysis

          -  Willing and able to provide informed consent

        Exclusion Criteria:

          -  Requirement of antiplatelet agent or oral anticoagulation, in the view of the treating
             physician

          -  Contraindication to aspirin

          -  Dialysis requirement due to acute kidney injure I with the expectation of kidney
             function recovery

          -  History of haemorrhagic stroke or intracranial bleed within the past 12 months

          -  Coagulopathy from any cause
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xueqing Yu</last_name>
    <role>Study Chair</role>
    <affiliation>Guangdong Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vlado Perkovic</last_name>
    <role>Study Chair</role>
    <affiliation>The George Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Muh Geot Wong</last_name>
    <role>Study Director</role>
    <affiliation>The George Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wei Chen</last_name>
    <role>Study Director</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Li Fan</last_name>
    <role>Study Director</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xueqing Yu</last_name>
    <phone>+86-20-83827812</phone>
    <email>yuxq@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Fan</last_name>
    <phone>+86-20-87755766-8174</phone>
    <email>fanli5@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianxin Wan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quanzhou No.1 Hospital</name>
      <address>
        <city>Quanzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shizhong Shen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tianxi Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Foshan No.1 people's hospital</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yaozhong Kong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial Peoples Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hua Du District People's Hospital of Guangzhou</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yunfang Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Panyu District people's hospital of Guangzhou</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Minyan Xie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Sixth Affiliated Hospital of Sun yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zongpei Jiang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hui Peng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiping Center Hospital</name>
      <address>
        <city>Kaiping</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenzhen No.2 people's hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhaoqing first people's hospital</name>
      <address>
        <city>Zhaoqing</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan City People's Hospital</name>
      <address>
        <city>Zhongshan</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Youjiang Ethnic Medicine College</name>
      <address>
        <city>Baise</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jie Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yunhua Liao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guizhou Province Peple's Hospital</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yan Zha</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hainan Provincial People's Hospital</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jiali Wei</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Central Hospital of Wuhan</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenli Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chun Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College of Huazhong Science and Technology University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Gang Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan No.1 People's Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Fei Xiong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yichang central people's hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lin Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaoyan Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hao Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiangcheng Xiao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Provincial People's Hospital</name>
      <address>
        <city>Shangsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yumei Liang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Inner Mongolia Medical University</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianrong Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ganzhou People's Hospital</name>
      <address>
        <city>Ganzhou</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hongxia Peng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangxi Province Peple's Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Aimin Zhong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yan Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sichuan Province People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Li Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fengqing People's Hospital of Yunnan Province</name>
      <address>
        <city>Lincang</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jinfeng Guo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianghua Chen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aspirin</keyword>
  <keyword>Dialysis</keyword>
  <keyword>End Stage Kidney Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified study data that supports the results will be shared following publication. Any sub-study analysis and publication will have to be reviewed and approved by the Trial Steering Committee, local Ethics and Regulatory requirements.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

